Welcome to Scientific Depth, i3's online information center that includes access to:

The Innovation Series

Articles, white papers and presentations that provide insight into the science and business of clinical research.

i3 InLine

Current and back issues of our monthly newsletter that presents unique i3 insights plus a summary of the top news impacting the pharma industry.

Engage

Current and back issues of our online newsletter offering timely insight into career matters, hiring practices, and workplace trends for clinical research professionals.

i3 Articles and White Papers

Published work and thought papers written by i3 specialists.

Case Studies

Reports on the results our clients have obtained by drawing on the specialized expertise of i3 scientists, researchers, and associated professionals, or from the use of our data products.

Scientific Presentations and Posters

Login or sign up now to gain access.

i3 InLine Spotlight Article:

Advances in Drug Development for Multiple Sclerosis Pose Clinical Research Challenges

Considerable growth in multiple sclerosis (MS) research has led to more potential drugs in the development pipeline than ever before,¹ creating a double-edged sword for this therapeutic area. Although the recent uptick in MS clinical studies is likely to yield several new therapies for MS patients, it has also resulted in a diminished pool of available clinical trial patient candidates in the United States and Europe, a factor that impacts the speed of new drugs coming to the market.

“In many ways, pharmaceutical companies developing new drugs for MS have become victims of their own success, because the more robust the pipelines of new compounds, the more competition there is for clinical trial sites and subjects,” according to Maria Lopez-Bresnahan, M.D., M.B.A., Vice President and Global Head, Medical and Scientific Affairs, i3 Research.

Read the entire article

Sign up now for access to the entire brief!

July 1, 2009
Source: i3 InLine